ERBB2 and neoplasm: Analysis of the splenocyte reactivity confirmed that the mice that received the combination treatment mounted a strong durable T cell response to both CT26-HER2 and CT26-wt tumor cells, i.e., to both HER2 and to the tumor neoantigens (Figure 5H).